Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Torex Gold Resources Analyst Ratings
Stephens & Co. Reiterates Overweight on 10x Genomics, Maintains $30 Price Target
CCORF Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $32
Leerink Partners Initiates 10x Genomics(TXG.US) With Buy Rating, Announces Target Price $35
Navigating 11 Analyst Ratings For 10x Genomics
10x Genomics Analyst Ratings
Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $46
Buy Rating Affirmed for 10x Genomics Amidst Strategic Realignment and Promising Growth Prospects
Stifel Nicolaus Reaffirms Their Buy Rating on 10x Genomics (TXG)
Maintaining Hold: Balancing 10x Genomics' Growth Prospects With Economic and Strategic Challenges
10x Genomics (TXG) Receives a Buy From Barclays
Hold Rating on 10x Genomics Amidst Mixed Financial Performance and Market Uncertainties
10x Genomics Analyst Ratings
CCORF Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $32
10x Genomics Price Target Cut to $32.00/Share From $50.00 by Canaccord Genuity
Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $32
CCORF Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $32
10x Genomics Price Target Maintained With a $24.00/Share by Jefferies
10x Genomics Analyst Ratings